Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 (paradigm™ 4)

Novo Nordisk logo

Novo Nordisk

Status and phase

Completed
Phase 3

Conditions

Haemophilia B
Congenital Bleeding Disorder

Treatments

Drug: nonacog beta pegol

Study type

Interventional

Funder types

Industry

Identifiers

NCT01395810
NN7999-3775
U1111-1121-5408 (Other Identifier)
2010-023072-17 (EudraCT Number)
JapicCTI-121812 (Registry Identifier)

Details and patient eligibility

About

This trial is conducted in Asia, Europe, Japan, North America and South Africa. The aim is to evaluate the safety and efficacy of nonacog beta pegol (NNC-0156-0000-0009) after long-term exposure in patients with haemophilia B. This trial is an extension to trials NN7999-3747 (NCT01333111/paradigm™ 2) and NN7999-3773 (NCT01386528/paradigm™ 3).

Enrollment

71 patients

Sex

Male

Ages

13 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Previous participation in NN7999-3747 (NCT01333111) and/or NN7999-3773

Exclusion criteria

  • Known history of FIX inhibitors based on existing medical records, laboratory report reviews and patient and LAR (legal acceptable representative) interviews
  • Current FIX inhibitors above or equal to 0.6 BU (Bethesda Units)
  • Congenital or acquired coagulation disorders other than haemophilia B
  • Previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records)
  • Any disease (liver, kidney, inflammatory and mental disorders included) or condition which, according to the Investigator's (trial physician) judgement, could imply a potential hazard to the patient, interfere with trial participation, or interfere with trial outcome

Trial design

71 participants in 4 patient groups

Prophylaxis, high dose (once weekly)
Experimental group
Treatment:
Drug: nonacog beta pegol
Prophylaxis, low dose (once weekly)
Experimental group
Treatment:
Drug: nonacog beta pegol
On-demand
Experimental group
Treatment:
Drug: nonacog beta pegol
Prophylaxis, high dose (every second week)
Experimental group
Treatment:
Drug: nonacog beta pegol

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems